Biotechnology

Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer

BENGALURU, India, Sept. 7, 2021 /PRNewswire/ -- Today, Jubilant Biosys Limited announced the appointment ofGiuliano Perfetti as its Chief Executive Officer. Mr. Giuliano Perfetti joins as CEO Jubilant Bio...

2021-09-07 16:11 6269

NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease

-- Using NeuExcell's neuroregenerative gene therapy platform, the collaboration aims to develop an effective and safe treatment for patients suffering from Huntington's Disease. -- Spark Therapeutics' excellence in R&D and proprietary adeno-associated virus (AAV) vector gene therapy platform ma...

2021-09-07 12:00 4505

Laureates of the 2021 Global Energy Prize Announced

MOSCOW, Sept. 6, 2021 /PRNewswire/ -- The winners of the 2021 Global Energy Prize  were announced on 6th September in Kazan. The laureates were: Russian scientists Zinfer Ismagilov and Suleyman Alak...

2021-09-06 20:00 4262

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announceSaibal Kar MD, FACC, FSCAI, board-certified interventional cardiologist has agreed to become our exclusive consultant in China to advise the research and development of our Mitral Transcatheter E...

2021-09-06 13:44 4618

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

SUZHOU, China, Sept. 5, 2021 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co.,Ltd. (hereinafter referred to as "GeneQuantum") and BrighGene Biomedical (Suzhou) Co.,Ltd. (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1...

2021-09-06 09:00 2024

AffaMed Therapeutics Enters into Strategic Partnership Agreement with Beijing Tiantan Hospital and Infinite Brain Technologies to Promote Digital Therapy in Neurological Diseases

BEIJING, Sept. 5, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, announced during the recent "China International Trade in Servi...

2021-09-06 08:00 1829

WuXi AppTec Receives AA ESG Rating from MSCI

SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of "corporate governance" and "product safety and quality...

2021-09-06 08:00 3735

The National Medical Products Administration (NMPA) issues product license for Abiraterone acetate 250 mg, Bioequivalance study conducted in India by Accutest Research Laboratories (I) Pvt. Ltd., one of the Top Indian CRO

BEIJING and MUMBAI, India, Sept. 6, 2021 /PRNewswire/ -- National Medical Products Administration  (NMPA) China, announces the approval of Abiraterone acetate 250mg ofQilu Pharmaceuticals for marketing purpose. Applicable Bioequivalance ...

2021-09-06 08:00 2868

Avidity Science Announces Agreement to Divest Lab Products & Harford Systems

WATERFORD, Wis., Sept. 4, 2021 /PRNewswire/ -- Avidity Science, a worldwide leader in life science research tools, today announces it has sold its subsidiaries of Lab Products, LLC. and Harford Systems, LLC. to Gen Cap America, Inc. ("Gen Cap"), a private equity firm focused on lower middle marke...

2021-09-04 00:00 5676

PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC

DAEJEON, South Korea, Sept. 3, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Ethics Committee (HREC) clearance to commence the Phase II c...

2021-09-03 20:00 2651

Arctic Vision Obtains China IND Clearance for Phase III Study of ARVN003, the First in China for Presbyopia Treatment

SHANGHAI, Sept. 2, 2021 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, today announced the clearance of the Investigational New Drug (IND) application for Phase III study of ARVN003 (pilocarpine microdose o...

2021-09-03 08:00 2680

Clinical trial provides preliminary evidence of a cure for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) and Long Covid

BURLINGAME, Calif., Sept. 3, 2021 /PRNewswire/ -- Cortene Inc. announces publication of its InTiME clinical trial in which a short subcutaneous infusion of its experimental drug, CT38, achieved sustained symptom improvement in ME/CFS.  The company intends to test CT38 in Long Covid, the post-acut...

2021-09-03 06:00 2496

Angel Yeast Launches Patented Saccharomyces Boulardii Bld-3, a Strain of Yeast Probiotic Effective Against Diarrhea

YICHANG, China, Sept. 2, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast" or "Angel"), a listed high-tech yeast company inChina, announced its nutritional R&D team has developed a new strain of yeast probiotic,Saccharomyces boulardii Bld-3 (S. boulardii Bld-3) ...

2021-09-02 22:43 6416

Insilico Medicine Appoints the Former Chief Medical Officer of Schering Plough, Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets

SHANGHAI and NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end AI-powered drug discovery company, today announced the appointment of Robert Spiegel as acting CMO to oversee the clinical translation of its preclinical pipeline assets. Dr. Spiegel brings over 35 years of exte...

2021-09-02 21:00 4445

I-Mab Added to FTSE Russell Global Equity Index Series

SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global Eq...

2021-09-02 20:00 6773

CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC

* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy * The new drug applic...

2021-09-02 08:05 4854

Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)

SAN FRANCISCO and SUZHOU, China, Sept. 2, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-09-02 08:00 6440

Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline

HONG KONG, Sept. 1, 2021 /PRNewswire/ -- Insilico Medicine is pleased to announce an R&D collaboration with Gray Matter, a longevity biotechnology company focused on peptide-based interventions against cognitive decline, age-related CNS diseases, and aging. This strategic partnership is intended ...

2021-09-01 22:08 4172

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Josh House as Chief Financial Officer

HOUSTON and SINGAPORE, Sept. 1, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the appointment of Josh House as Chief Financial Officer, effective immediately. Dr....

2021-09-01 17:00 1851

WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date

* Successfully completed 12 regulatory inspections so far this year WUXI, China, Sept. 1, 2021 /PRNewswire/ -- WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has received the Manufacturing License fromJapan'...

2021-09-01 14:12 4175
1 ... 349350351352353